Effectiveness of guselkumab in patients with moderate-to-severe plaque psoriasis: a retrospective study from China

Eur J Dermatol. 2024 Feb 1;34(1):73-78. doi: 10.1684/ejd.2024.4599.

Abstract

Data on guselkumab as treatment for moderate-to-severe plaque psoriasis, especially in different body regions, in China is limited. This study aimed to estimate the effectiveness of guselkumab in Chinese patients with moderate-to-severe plaque psoriasis, including effectiveness at different body regions. This multicentre, observational study retrospectively enrolled patients with moderate-to-severe plaque psoriasis. Effectiveness outcome was based on Psoriasis Area and Severity Index (PASI) response and improvement in Body Surface Area (BSA) and Dermatology Life Quality Index (DLQI). A total of 51 patients were included, with a median age of 44.00 (18.00, 74.00) years and median duration of psoriasis of 10.00 (0.50, 55.00) years. After 20 weeks of treatment, PASI response with 75% improvement from baseline (PASI 75) was reported in 96.1% of patients; 72.5% of patients achieved a DLQI score of 0-1 at week 20. The percentage of affected BSA was significantly decreased at week 4 (p<0.05), week 12 (p<0.001) and week 20 (p<0.001). PASI score significantly changed from baseline after four weeks (p<0.001), 12 weeks (p<0.001) and 20 weeks of treatment (p<0.001). DLQI score significantly increased at week 4 (p<0.001), week 12 (p<0.001) and week 20 (p<0.001). PASI 75 was achieved for the upper limbs in all cases and 100% PASI improvement (PASI 100) in 89.1%. The head and lower limbs were the areas least responsive to treatment, with PASI 100 achieved in only 68.6% and 70.6%, respectively. Guselkummab provided rapid and sustained PASI improvement, especially for the skin of the upper limbs and body trunk.

Keywords: effectiveness; guselkumab; head; lower limb; psoriasis; trunk.

Publication types

  • Multicenter Study
  • Observational Study

MeSH terms

  • Antibodies, Monoclonal*
  • Antibodies, Monoclonal, Humanized*
  • China
  • Humans
  • Psoriasis* / drug therapy
  • Retrospective Studies
  • Severity of Illness Index
  • Treatment Outcome

Substances

  • guselkumab
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized